DCC-2036 CAS NO.1020172-07-9

We have been providing over 1000 products including molecular targeted anticancer drugs, cell signaling pathway

inhibitors, pharmaceutical intermediates, and heterocyclic compounds, and quality services including custom

synthesis, transfer of new drug patent and technology, technical cooperation, and process optimization.

Jinan Trio PharmaTech was founded by a core group of top overseas pharmaceutical chemists, Medical scientists and

business management experts, and is an enterprise of science and technology supported by the "Attracting High-

Level Talent Scheme" of Jinan government.

Jinan Trio PharmaTech Co., Ltd. 

Year Establishment: 2008

Location: We are located at one of the largest National Technical Integrated Drug Discovery Platforms in the High-Tech Zone of Jinan City

Our company was founded by a core group of top overseas pharmaceutical chemists, medical scientists business

management experts

We have built up solid cooperation with over twenty oversea companies over one hundred domestic companies

since the foundation

Specifications:

Name  DCC-2036

Synonyms  N-[3-tert-Butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl]-N'-[2-fluoro-4-[(2-(methylcarbamoyl)pyridin-4-yl)oxy]phenyl]urea

Molecular Formula  C₃₀H₂₈FN₇O₃

Molecular Weight  553.59

CAS Registry Number  1020172-07-9
 

Applications:

DCC-2036 is a conformational control inhibitor of Abl1 and Abl1-T315I with IC50s of 0.8 nM and 4 nM, respectively.